Study summary · research use only
[Thymalin in the combined treatment of parkinsonism patients]
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This human clinical trial examined fifteen patients with idiopathic parkinsonism, aged 45 to 72 years (UPDRS stages 1.5 to 2.5), before and after a course of treatment with thymalin. The authors describe a positive time-related change in the patients' general physical and mental well-being and in the parkinsonian triad of tremor, rigidity, and hypokinesia, alongside measures they used to characterize central nervous system integrative function. They report EEG mapping changes, including a significant decrease in alpha-rhythm power in the anterocentral brain regions, which the authors interpret as a change in cortical neurodynamics. The abstract describes no control group or comparative statistics.
Abstract
Overall, fifteen patients with stage IB-2A (stages 1.5 to 2.5 as per UPDRS scale) idiopathic parkinsonism who ranged from 45 to 72 years old were examined before and after the course of treatment with thymalin. A positive time-related course was noted of the patients' general physical/mental well-being, parkinsonian triad of symptoms (tremor, rigidity, hypokinesia) associated with objective parameters characterizing the state of cerebral integrative functions (by the method of determining the biological age of the central nervous system). Efficacy of thymolin use is confirmed by EEG mapping; there has been established a significant decrement in the power of alpha rhythm in the anterocentral regions of the brain, which fact suggests to us an improvement in the cortical neurodynamics.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.